Geographic Atrophy treatment to move to Phase II Geographic Atrophy treatment to move to Phase II Geographic Atrophy treatment BI 771716 to move to Phase II, following positive Phase I results
CHMP recommends new treatment for chronic kidney disease CHMP recommends new treatment for chronic kidney disease The CHMP of EMA has granted a positive opinion recommending empagliflozin for the treatment of adults with chronic kidney disease
emperor-preserved-heart-failure-full-data emperor-preserved-heart-failure-full-data Full results from EMPEROR-Preserved trial demonstrate significant improvement in heart failure outcomes in adults with preserved ejection fraction